Buparlisib Hydrochloride
- CAS No.
- 1312445-63-8
- Chemical Name:
- Buparlisib Hydrochloride
- Synonyms
- CS-2154;BKM 120AAA;NVP-BKM120 HCl;Buparlisib HCl;BKM-120 (HCl salt);NVP-BKM120 HCl salt;BKM120 hydrochloride;BKM-120 hydrochloride;BKM 120 hydrochloride;NVP-BKM120 (HYDROCHLORI
- CBNumber:
- CB72624269
- Molecular Formula:
- C18H22ClF3N6O2
- Molecular Weight:
- 446.86
- MOL File:
- 1312445-63-8.mol
- Modify Date:
- 2024/7/2 8:55:16
| storage temp. | Store at -20°C |
|---|---|
| solubility | ≥44.7 mg/mL in DMSO; ≥52.8 mg/mL in H2O with gentle warming; ≥96 mg/mL in EtOH with gentle warming |
| form | solid |
| color | White to yellow |
| InChI | InChI=1S/C18H21F3N6O2.ClH/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27;/h9-11H,1-8H2,(H2,22,23);1H |
| InChIKey | DGPLYAXBXJXEID-UHFFFAOYSA-N |
| SMILES | C(C1=CC(N)=NC=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=C1)(F)(F)F.Cl |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS08,GHS09,GHS06 |
|---|---|
| Signal word | Danger |
| Hazard statements | H372-H400-H341-H300-H411 |
| Precautionary statements | P260-P264-P270-P314-P501-P264-P270-P301+P310-P321-P330-P405-P501-P273-P391-P501-P201-P202-P281-P308+P313-P405-P501 |
Buparlisib Hydrochloride Chemical Properties,Uses,Production
Definition
Buparlisib hydrochloride (BKM120 Hydrochloride) is an investigational small molecule orally available pan-class I phosphoinositide 3-kinase inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
Mode of action
Buparlisib specifically inhibits class I PIK3 in the PI3K/AKT kinase signaling pathway in an ATP-competitive manner, thus inhibiting the production of the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate and activation of the PI3K signaling pathway. This may induce inhibition of tumour cell growth and survival in susceptible tumour cell populations. Buparlisib is currently under investigation in patients with a variety of solid tumours, including breast cancer[1].
References
[1] Carmen Criscitiello. “Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.” Breast Cancer?: Targets and Therapy 10 (2018): 23–29.
Buparlisib Hydrochloride Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 | China | 294 | 58 | Inquiry |
| Aladdin Scientific | +1-+1(833)-552-7181 | United States | 52927 | 58 | Inquiry |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | China | 32760 | 60 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29897 | 58 | Inquiry |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | China | 39916 | 58 | Inquiry |
| Zhengzhou Alfa Chemical Co.,Ltd | +8618530059196 | China | 13184 | 58 | Inquiry |
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | United States | 19892 | 58 | Inquiry |
| InvivoChem | +1-708-310-1919 +1-13798911105 | United States | 6393 | 58 | Inquiry |
| Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 | China | 49739 | 58 | Inquiry |
| Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | China | 3136 | 58 | Inquiry |
1312445-63-8(Buparlisib Hydrochloride)Related Search:
1of4
chevron_right